You are here: Industry Insights > NICE

News List

NICE recommends ravulizumab for treatment of a rare blood disorder europeanpharmaceuticalreview
April 26, 2021
On the NICE’s recommendation, ravulizumab will be made available to hundreds of patients with paroxysmal nocturnal haemoglobinuria on the UK’s NHS.
Novartis’ MS therapy Kesimpta wins NICE backing pharmatimes
April 22, 2021
Novartis’ Kesimpta has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of relapsing remitting multiple sclerosis (RRMS) in adult patients.
NICE’s five-year strategy sets a ‘positive vision for the future’ pharmatimes
April 21, 2021
The pharma industry has responded to the National Institute for Health and Care Excellence’s (NICE) new five-year strategy, announced yesterday.
Enhertu accepted via cancer drugs fund for HER2-positive breast cancer pharmatimes
April 21, 2021
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu for use within the cancer drugs fund (CDF) for the treatment of previously-treated HER2-positive metastatic breast cancer.
NICE unveils new strategy to improve patient access to innovative treatments pharmatimes
April 20, 2021
The National Institute for Health and Care Excellence (NICE) has unveiled new guideline recommendations with the aim of providing accelerated patient access to new treatments and innovations.
NICE recommends Alexion’s PNH treatment Ultomiris pharmatimes
April 19, 2021
The National Institute for Health and Care Excellence (NICE) has recommended Alexion’s C5 complement inhibitor Ultomiris for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).
NICE publishes new guidance on chronic pain management pharmatimes
April 15, 2021
The UK National Institute for Health and Care Excellence (NICE) has published new guidance on the assessment of chronic pain, recommending exercise instead of commonly used drugs such as paracetamol as part of its guidelines.
NICE 'no' for Opdivo/Yervoy lung cancer combo pharmatimes
April 13, 2021
The National Institute for Health and Care Excellence (NICE) has issued a preliminary no for NHS use of Bristol-Myers Squibb's Opdivo (nivolumab)/Yervoy (ipilimumab) combination for treating a certain lung cancer.
NICE backs restricted use of Ondexxya pharmatimes
April 07, 2021
NHS cost regulators have backed funding for Alexion's Ondexxya (andexanet alfa) to reverse anticoagulation of the direct factor Xa (FXa) inhibitors apixaban or rivaroxaban in adults who experience a life-threatening or uncontrolled bleed in the ...
Thousands to benefit from five-minute breast cancer treatment pharmatimes
April 07, 2021
NHS England is rolling out an injection that dramatically cuts the amount of time breast cancer patients spend in hospital from two and a half hours to as little as five minutes across the country, following a deal with its manufacturer Roche.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page